Topical BRAF Inhibitor Composition for EGFR-Induced Acneiform Lesions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing EGFR, PI3K, and MEK inhibitors used in cancer treatment cause severe cutaneous adverse reactions such as acneiform lesions, leading to treatment discontinuation and poor patient compliance.
Innovation Solution
A topical pharmaceutical composition containing 0.03% to 0.1% w/w of a compound of Formula IV, combined with a pharmaceutically acceptable carrier, is administered to the skin for 4 to 6 weeks to treat and prevent these adverse reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EGFR inhibitors are used to treat cancer, then cancer treatment efficacy is improved, but severe cutaneous adverse reactions occur
Solution Approach 1:
The treatment approach is segmented into two separate components: systemic EGFR inhibitor administration for cancer treatment and topical BRAF inhibitor application for skin reaction management. This segmentation allows independent optimization of each treatment modality without mutual interference, resolving the contradiction between cancer efficacy and skin tolerance
Solution Approach 2:
A topical BRAF inhibitor composition acts as an intermediary agent that mediates the skin reactions caused by EGFR inhibitors. The BRAF inhibitor locally counteracts the downstream signaling effects of EGFR inhibition in skin cells, preventing acneiform lesions while not interfering with the systemic anti-cancer activity
2Reliability
If topical composition with high concentration of BRAF inhibitor is used, then skin reaction treatment efficacy is improved, but risk of systemic side effects increases
Solution Approach 1:
The composition is designed for localized topical application to affected skin areas only, creating a local high concentration of BRAF inhibitor where it is needed to treat skin reactions, while maintaining low or negligible systemic exposure. This local quality approach maximizes therapeutic effect at the application site while minimizing systemic side effects
Solution Approach 2:
The treatment transitions from systemic administration (one dimension) to topical localized application (another dimension - spatial distribution). By changing the dimension of drug delivery from systemic circulation to localized skin application, the patent achieves high local efficacy while avoiding systemic toxicity
3Reliability
If topical composition is administered frequently, then treatment effectiveness is improved, but patient compliance becomes difficult
Solution Approach 1:
The composition is formulated and dosed to achieve effective treatment with once-daily application. This periodic action pattern balances therapeutic effectiveness with patient convenience, making it easier for patients to comply with the treatment regimen compared to multiple daily applications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces the severity of acneiform lesions from grades 4 to 0, improving patient compliance and reducing treatment discontinuation.
Implementation Method 1
Topical BRAF inhibitor compositions for treatment of EGFR downstream effectors - induced reactions
Implementation Method 2
compound of Formula IV, i.e. LUT014, for treating EGFR downstream effectors-induced cutaneous reactions
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 1E~1F
AI summary
Pharmaceutical topical compositions comprising compound of Formula IV and method of using pharmaceutical topical compositions comprising compound of Formula IV for the treatment or prevention of EGFR inhibitor, PI3K inhibitor, MEK inhibitor and/or HER dimerization inhibitor-induced acneiform lesions in a subject in need thereof are provided.